Scilex Holding Company (SCLX)
| Previous close | 1.8800 |
| Open | 1.9600 |
| Bid | 1.8400 x 100 |
| Ask | 2.0300 x 100 |
| Day's range | 1.8900 - 1.9650 |
| 52-week range | 0.7320 - 6.5500 |
| Volume | |
| Avg. volume | 1,133,045 |
| Market cap | 236.186M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
GlobeNewswireScilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announc
- GlobeNewswire
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year.Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year.Total product net sales for the quarter ended June 2024 grew in the range of 30% to 44%, compared to the same period last year. PALO ALTO,
- GlobeNewswire
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and
